Related Experiment Video
Updated: Jul 13, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection
1Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA. dimitrov@profectusbiosciences.com
Abstract:
Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal antibody specific for CD4, for the potential treatment of HIV infection. In August 2006, the FDA advised Tanox to conduct additional dose-finding studies, from which data could potentially be used in a BLA filing. Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Retrovirus Life Cycles
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...

